EMDAC Makes CV Safety Top Priority in Obesity Drugs
By Mari Serebrov
Friday, March 30, 2012
Cardiovascular safety won out over all other risk factors and the need to encourage the development of innovative weight-loss drugs Thursday as the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 17-6 that cardiovascular outcome trials (CVOTs) should be required for all obesity drugs, even those that have no theoretic cardiovascular risk or signal.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.